<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482752</url>
  </required_header>
  <id_info>
    <org_study_id>SAV006-03</org_study_id>
    <nct_id>NCT03482752</nct_id>
  </id_info>
  <brief_title>Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis</brief_title>
  <acronym>IMPALA-EX</acronym>
  <official_title>An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Savara Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Savara Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial for subjects with autoimmune pulmonary alveolar proteinosis (aPAP) who have
      completed the IMPALA trial (NCT02702180).

      At the Baseline visit, eligible subjects may continue or re-start treatment with 300 µg
      inhaled molgramostim (recombinant human Granulocyte-Macrophage Colony Stimulating Factor;
      GM-CSF) administered intermittently in cycles of seven days molgramostim, administered once
      daily, and seven days off treatment.

      Subject will be treated with inhaled molgramostim for up to 36 months.

      During the trial, whole lung lavage will be applied as rescue therapy.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">April 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label, Non-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse drug reactions</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events leading to treatment discontinuation</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alveolar-arterial oxygen gradient</measure>
    <time_frame>36 months</time_frame>
    <description>Difference in oxygen tension between lungs and blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St Georges Respiratory Questionnaire total score</measure>
    <time_frame>36 months</time_frame>
    <description>Respiratory-specific questionnaire measuring impact on overall health, daily life, and perceived well-being. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of whole lung lavages during the trial</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion capacity of the lung for carbon monoxide</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen tension</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary alveolar proteinosis Disease Severity Score</measure>
    <time_frame>36 months</time_frame>
    <description>Disease-specific score graded based on symptoms of PAP and oxygenation of blood. Scores range from 1 to 5, where 5 indicates most severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for oxygen supplement therapy</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects not requiring treatment for pulmonary alveolar proteinosis</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time off treatment for pulmonary alveolar proteinosis</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autoimmune Pulmonary Alveolar Proteinosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molgramostim</intervention_name>
    <description>300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.</description>
    <other_name>Recombinant human GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completer of the IMPALA trial.

          -  Females who have been post menopausal for &gt;1 year, or females of child-bearing
             potential who are not pregnant or lactating and are using acceptable contraceptive
             methods.

          -  Males agreeing to use using acceptable contraceptive methods.

          -  Willing and able to provide signed informed consent.

        Exclusion Criteria:

          -  Treatment with GM-CSF products other than molgramostim nebuliser solution within three
             months of Baseline.

          -  Treatment with any investigational medicinal product other than inhaled molgramostim
             within four weeks of Baseline.

          -  History of allergic reactions to GM-CSF.

          -  Connective tissue disease, inflammatory bowel disease or other autoimmune disorder
             requiring treatment associated with significant immunosuppression, e.g. more than 10
             mg/day systemic prednisolone.

          -  Previous experience of severe and unexplained side effects during aerosol delivery of
             any kind of medicinal product.

          -  History of, or present, myeloproliferative disease or leukaemia.

          -  Apparent pre-existing concurrent pulmonary fibrosis.

          -  Any other serious medical condition which in the opinion of the investigator would
             make the subject unsuitable for the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bonella, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interstitial and Rare Lung Disease Unit, Ruhrlandklinik University Hospital, Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Of Respiratory Diseases &amp; Allergy</name>
      <address>
        <city>Århus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hospital Pontchaillou, Service de Pneumologie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Essen Westdeutsches Lungenzentrum am Universitätsklinikum Essen GmbH</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München - Gauting Klinik für Pneumologie</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitätsklinikum Heidelberg Abteilung für Pneumologie und Beatmungsmedizin</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Zentralklinikum Lübeck Medizinische Klinik III - Pneumologie</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital 2nd Pulmonary Department Athens Medical School National and Kapodistrian University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Institute of Pulomonary Medicine</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Pneumologia Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov first Saint Petersburg State Medical Univerisity</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Of Intensive Care Unit Royal Brompton Hospital London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

